ArticleCureus2025
Thyroid Dysfunction in Patients With End-Stage Renal Disease: A Single-Centered Experience From Pakistan.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between hypothyroidism, levothyroxine replacement and kidney function outcomes: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Article
- Understanding the Drivers of Hypothyroidism in Patients Undergoing Chronic Hemodialysis.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction The global prevalence of chronic kidney disease (CKD) is increasing due to diabetes and hypertension, with a substantial number of patients progressing to end-stage renal disease (ESRD) requiring maintenance dialysis. Thyroid dysfunction, particularly hypothyroidism, is common in CKD and ESRD patients but is often underdiagnosed due to symptom overlap with uremia. This study aimed to determine the prevalence of thyroid dysfunction in hemodialysis patients at the Sindh Institute of Urology and Transplantation (SIUT), Karachi. Methods A prospective cross-sectional study was conducted, enrolling 131 patients on maintenance hemodialysis for at least three months. Participants' demographic and clinical data were collected, and blood samples were taken for thyroid function testing using an Access hypersensitive thyroid-stimulating hormone (hTSH) immunoassay system. Statistical analyses were performed using SPSS version 22.0 (IBM Corp., Armonk, NY), with a significance threshold of p < 0.05. Results The total population included in the study was 131. Out of them, 74 (56.5%) were males. The study population had a mean age of 56.4 years. Hypertension and diabetes were the most common comorbidities noticed in 73 (55.7%) and 14 (10.7%) patients, respectively. Hypothyroidism was observed in 27 (20.6%) patients, with 18 (66.7%) of them having overt hypothyroidism. Hyperthyroidism was observed in four (3.1%) patients, all subclinical. Significant risk factors for hypothyroidism included female gender, longer duration on hemodialysis, decreased total leukocyte and platelet counts, and increased serum urea and creatinine levels. Conclusion The study underscores the significant burden of thyroid dysfunction in ESRD patients on hemodialysis, emphasizing the need for regular screening and management to mitigate associated cardiovascular risks and improve patient outcomes. Future studies should explore the long-term benefits of routine thyroid screening and the impact of different dialysis modalities on thyroid function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.